

Follicular Lymphoma Market to Exhibit Rapid Growth Rate During Forecast Period (2023-2032), Investigates DelveInsight

DelveInsight's Follicular Lymphoma Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, June 5, 2024 /EINPresswire.com/ -- DelveInsight's "Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Follicular Lymphoma Market Forecast](#)

Some of the key facts of the Follicular Lymphoma Market Report:

The Follicular Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies. The FDA is expected to make a decision by March 31, 2024. According to the SEER database, the incidence of FL in the US is 2.6/100,000 men per year based on cases from 2015 to 2019 that have been aged appropriately. 25% of all FL cases were in stage I, 15% in stage 2, 26% in stage 3, 27% in stage 4, and 7% were in stage IV

In November 2023, Bayer, a multinational pharmaceutical company based in Germany, has revealed its intention to withdraw the new drug application for Aliqopa (copanlisib) in the United States. This decision follows the disappointing outcome of a clinical trial focused on treating relapsed follicular lymphoma (FL). After discussions with the US Food and Drug Administration

(FDA) regarding the trial results, Bayer opted to discontinue the application. Aliqopa was being evaluated as a potential treatment option for adult patients with relapsed follicular lymphoma who had undergone at least two prior systemic therapies.

Approximately 90% of Follicular Lymphomas possess one or more mutations in genes involved in epigenetic regulation through histone modifications (KMT2D, CREBBP, and EZH2) and chromatin remodelling (HIST1H1B-E, ARID1A), according to a research by Perrett and Okosun (2021). KMT2D, CREBBP, and EP300 are present in 60–80%, 70%, and 15%, respectively, of FL cases

In accordance with a research by Liu W. et al. (2021), 10–20% of patients receiving immunochemotherapy relapse after 24 months of diagnosis, and these patients fare much worse than those who do not. Low, moderate, and high risk were distributed at 36%, 37%, and 27%, respectively

Incidence cases of Follicular Lymphoma are roughly 3,300, 2,900, 2,800, 1,700, and 2,800 in Germany, France, Italy, Spain, and the UK, respectively, according to a study by Kanas et al. (2021).

With tremendous success over the years, businesses all around the world are diligently working towards the creation of revolutionary remedies. The management of FL is showing promise from major players like Novartis Pharmaceuticals, Genentech/Roche, Xynomic Pharmaceuticals, MEI Pharma, Epizyme, Innovent Biologics, etc.

Some of the most eagerly anticipated new medicines that are pending approval include Kymriah (tisagenlecleucel), ME-401, Abexinostat, Tazemetostat, Parsaclisib (IBI376), and others.

Key Follicular Lymphoma Companies: Roche, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others

Key Follicular Lymphoma Therapies: Mosunetuzumab, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others

The Follicular Lymphoma epidemiology based on risk analyzed that low risk, intermediate risk and high risk patients contribute to 20%, 53% and 27% of all FL cases, respectively

The Follicular Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

Follicular Lymphoma Overview

Follicular Lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), which is a cancer of the lymphatic system. It originates from B lymphocytes (B cells), a type of white blood cell that plays a crucial role in the immune system. Follicular Lymphoma is characterized by the formation of abnormal, usually slow-growing, lymphoid follicles in the lymph nodes.

Get a Free sample for the Follicular Lymphoma Market Report:

https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:

The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Follicular Lymphoma

Prevalent Cases of Follicular Lymphoma by severity

Gender-specific Prevalence of Follicular Lymphoma

Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ [Follicular Lymphoma Epidemiology Forecast](#)

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Follicular Lymphoma Therapies and Key Companies

Mosunetuzumab: Roche

Abexinostat: Xynomic Pharmaceuticals

ME-401: MEI Pharma

Tisagenlecleucel: Novartis

Parsaclisib (IBI376): Innovent Biologics

Odronextamab: Regeneron

Mosunetuzumab: Genetech

Abexinostat: Xynomic Pharma
Rituximab IV: Roche
Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
Enzastaurin: Eli Lilly and Company
Loncastuximab tesirine: ADC Therapeutics S.A
Zanubrutinib: BeiGene
Bendamustine: Cephalon
Tazemetostat: Epizyme, Inc.
ibrutinib: Pharmacyclics LLC.
Obatoclax mesylate: Gemin X
Ibrutinib: AbbVie
IXAZOMIB: Millennium Pharma

Follicular Lymphoma Market Strengths

Follicular lymphoma market has a diverse pipeline, with emergence of novel classes such as bi-specific antibodies, cancer vaccine and allogenic CAR-Ts.

Follicular Lymphoma Market Opportunities

R-CHOP continues to be the gold standard of care despite other therapies or combinations that have tried to advance the treatment paradigm

Scope of the Follicular Lymphoma Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Follicular Lymphoma Companies: Roche, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others

Key Follicular Lymphoma Therapies: Mosunetuzumab, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others

Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies

Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Follicular Lymphoma Unmet Needs, KOL's views, Analyst's views, Follicular Lymphoma Market Access and Reimbursement

Discover more about therapies set to grab major Follicular Lymphoma market share @ [Follicular](#)

[Lymphoma Treatment Landscape](#)

Table of Contents

1. Follicular Lymphoma Market Report Introduction
2. Executive Summary for Follicular Lymphoma
3. SWOT analysis of Follicular Lymphoma
4. Follicular Lymphoma Patient Share (%) Overview at a Glance
5. Follicular Lymphoma Market Overview at a Glance
6. Follicular Lymphoma Disease Background and Overview
7. Follicular Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Follicular Lymphoma
9. Follicular Lymphoma Current Treatment and Medical Practices
10. Follicular Lymphoma Unmet Needs
11. Follicular Lymphoma Emerging Therapies
12. Follicular Lymphoma Market Outlook
13. Country-Wise Follicular Lymphoma Market Analysis (2019–2032)
14. Follicular Lymphoma Market Access and Reimbursement of Therapies
15. Follicular Lymphoma Market Drivers
16. Follicular Lymphoma Market Barriers
17. Follicular Lymphoma Appendix
18. Follicular Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/717468318>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

